Background:
Sartans are mostly used as a part of combination with additional medicines
in the therapy of essencial hypertension. Preferred combinations are ARB and thiazide diuretics (Hydrochlorothiazide
(HCT) and Chlorthalidone (CHL)) or ARB and calcium antagonists. The number
of sartans mostly prescribed by specialists is only seven - Candesartan (CDS), Eprosartan (EPS),
Irbesartan (IBS), Losartan (LOS), Olmesartan (OMS), Telmisartan (TMS) and Valsartan (VLS).
Methods:
The widespread use of sartans in the treatment of hypertension requires reliable methods of
analysis. Bulk drugs and pharmaceutical preparations should be analyzed to ensure the quality of the
medicinal products reaching patients. On the other hand, the analysis of drugs in biological fluids
aims to trace and improve patient care by adjusting the therapeutic doses of drugs. According to our
knowledge, a review devoted to the analysis of sartans was published in 2014.
Results:
Spectral methods are widely used in the analysis of bulk drugs and pharmaceutical dosage
forms due to their relatively simple procedures, low reagent and sample consumption, speed, precision
and accuracy combined with accessibility and comparatively low cost of common apparatus.
Many papers for determination of sartans in bulk drugs and pharmaceutical preparations based on
liquid chromatographic techniques were published in the available literature. Among these methods,
HPLC takes the leading place but UPLC and HPTLC are also present.
Conclusion:
The widespread use of sartans in the treatment of hypertension requires reliable methods
of analysis. Bulk drugs and pharmaceutical preparations should be analyzed to ensure the quality
of the medicinal products reaching patients. On the other hand, the analysis of drugs in biological fluids
aims to trace and improve patient care by adjusting the therapeutic doses of drugs. Since 2014,
many articles have been published on the sartans analysis and this provoked our interest to summarize
the latest applications in the analysis of sartans in pharmaceutical formulations and biological
media. Articles published from 2014 to 2018 are covered.
Is cannabidiol hepatotoxic or hepatoprotective: A review
